Oral comments before the Federal Trade Commission on PBM Practices

Carl Schmid commented before the Federal Trade Commission on how PBM practices like copay accumulators and designating certain medications as “non-essential health benefits” allow PBMs and insurers to make more money and profit at the expense of patients who are having trouble affording their drugs.